SCHEMBL22714752

SCHEMBL22714752

COc1cc(-c2ncc(C)s2)cc2c(NCc3nc(C(F)(F)F)no3)ncnc12

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 9/20 0.36
LMNA P02545 6/20 0.36
USP2 O75604 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C19 P33261 2/20 0.36
HIF1A Q16665 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CLK4 Q9HAZ1 2/20 0.35
MAPK1 P28482 2/20 0.35
P2RX3 P56373 3/20 0.34
P2RX2 Q9UBL9 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29676272 0.88 PDE5A (0.39) PDE5ALMNAUSP2ALDH1A1CYP1A2
SCHEMBL28675697 0.88 PDE5A (0.39) PDE5ALMNAUSP2ALDH1A1CYP1A2
SCHEMBL22714755 0.85 PDE5A (0.37) PDE5ALMNAUSP2ALDH1A1CYP1A2
SCHEMBL24674487 0.84 LMNA (0.40) LMNAUSP2ALDH1A1CYP1A2CYP3A4
SCHEMBL22714679 0.81 PDE5A (0.42) PDE5ALMNAUSP2ALDH1A1CYP1A2
SCHEMBL22714691 0.79 CNR1 (0.43) PDE5ALMNAUSP2ALDH1A1CYP1A2
SCHEMBL29676562 0.79 CNR1 (0.43) PDE5ALMNAUSP2ALDH1A1CYP1A2
SCHEMBL22715541 0.78 PDE5A (0.39) PDE5AALDH1A1KDM4ECLK4P2RX3
SCHEMBL29676421 0.78 PDE5A (0.39) PDE5AALDH1A1KDM4ECLK4P2RX3
SCHEMBL22714830 0.76 PDE5A (0.40) PDE5ALMNAUSP2ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US claimed
CN-113891745-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 CN claimed
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER LABORATORIES, INC. 2022-07-21 US claimed
EP-3976180-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2022-04-06 EP claimed
CN-113891745-A As P2X3Aminoquinazoline derivatives as inhibitors 奇斯药制品公司 2022-01-04 CN claimed
WO-2020239952-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-03 WO claimed
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US disclosed
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER LABORATORIES, INC. 2022-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 PDE5A 103/4885LMNA 3348/4885USP2 3470/4885
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX5, P2RX1 PDE5A 103/4885LMNA 3348/4885USP2 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.